DESTINOR

pharmaceutical preparations, namely, biopharmaceuticals based on human monoclonal antibodies for the treatment of immune and inflammatory diseases and disorders, cardiovascular diseases and disorders, metabolic diseases and disorders, central nervous system diseases and disorders, and infectious-related disseases and disorders